Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA phase 3 trial of vericiguat in chronic heart failure with reduced ejection fraction
MOH_2017-03-20_000145Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat with Placebo (2 arms). Started Jun 2016; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2017-03-20_000145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-20_000145.